We selected patients who received TPO-RA at non-CR in the tapering phases of the course of prednisolone treatment because the effects of different second therapies for ITP according to the recommendations in the guidelines were unclear. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.